x

Posted 05 October, 2022

ASSEMBLY BIOSCIENCES, INC. appointed new CEO

CEO Change detected for ticker Nasdaq:ASMB in a 8-K filed on 05 October, 2022.


  On October 5, 2022, Assembly Biosciences, Inc. (the "Company") issued a press release announcing that, as part of a planned succession process, John G. McHutchison, A.O., M.D. will retire from his role as Chief Executive Officer of the Company, effective December 31, 2022.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of ASSEMBLY BIOSCIENCES, INC.
Health Care/Life Sciences • Pharmaceuticals
Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses on two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin and Derek A. Small on October 7, 2005 and is headquartered in South San Francisco, CA.
Market Cap
$91.3M
View Company Details
ASSEMBLY BIOSCIENCES, INC. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 5, 2022, Assembly Biosciences, Inc. (the "Company") issued a press release announcing that, as part of a planned succession process, John G. McHutchison, A.O., M.D. will retire from his role as Chief Executive Officer of the Company, effective December 31, 2022. Jason A. Okazaki, 46, the Company's President and Chief Operating Officer has been appointed President and Chief Executive Officer and a member of the Company's Board of Directors (the "Board"), each effective January 1, 2023. Dr. McHutchison, who was appointed Chief Executive Officer in 2019, will remain a Board member and will assume the role of Chairman of the Board's Science and Technology Committee effective January 1, 2023.

Since joining the Company in 2020, Mr. Okazaki has held positions of increasing responsibility with the Company. Mr. Okazaki served as the Company's Chief Legal and Business Officer from March 2020 until August 2021, when he was elected Chief Operating Officer. Mr. Okazaki was elected to serve as the Company's President effective August 1, 2022 and has since served as President and Chief Operating Officer. Further details of Mr. Okazaki's business experience are included in the "Executive Officers" section of the Company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 12, 2022.

There are no arrangements or understandings between Mr. Okazaki and any other person pursuant to which he was elected to serve as Chief Executive Officer. There are also no family relationships between Mr. Okazaki and any director or executive officer of the Company, and Mr. Okazaki has no direct or indirect interest in any transaction or proposed transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

The Company will report any compensation arrangements related to the transition after determination by the Compensation Committee of the Board.